3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
12
Meningioma
4
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Breast Neoplasms
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
X-Rays
8
Specimen Handling
8
Cyclophosphamide
8
Phantoms, Imaging
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
cabozantinib
5
Gemcitabine
5
Biopsy
5
Nuclear Medicine Department, Hospital
4
Methotrexate
4
Doxorubicin
4
fludarabine phosphate
3
Ifosfamide
3
Cisplatin
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
mifamurtide
2
larotrectinib
2
ivosidenib
2
irinotecan sucrosofate
2
ensartinib
2
atezolizumab
2
Vincristine
2
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
lutetium Lu 177 dotatate
×
90 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled